Chemo-immunotherapy combination, by enhancing IL-2 levels and employing the mAb Cetuximab, potentiates the anti-tumor activity of immune effector cells (such as \documentclass[12pt]{minimal}\usepackage{amsmath}\usepackage{wasysym}\usepackage{amsfonts}\usepackage{amssymb}\usepackage{amsbsy}\usepackage{mathrsfs}\usepackage{upgreek}\setlength{\oddsidemargin}{-69pt}\begin{document}$$\hbox {CD8}^{+}$$\end{document}T cells and NK cells), leading to effective tumor control25. Here, CD8A is linked to neoplasm.